Want to see CH:ADXN full AI Analyst Report?
ADXN Stock Chart & Stats
CHF0.03
CHF0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeCHF0.03 - CHF0.09
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.15M
Market Cap
CHF3.18M
Enterprise ValueCHF3.74
Total Cash (Recent Filing)CHF937.50K
Total Debt (Recent Filing)CHF102.27K
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding218,654,500
10 Day Avg. Volume3,209,522
30 Day Avg. Volume1,145,783
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.30
Price to Sales (P/S)35.91
P/FCF Ratio-2.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline Scientific ProgressRobust, cross-species preclinical efficacy and a favorable respiratory safety margin support the cough program’s development case. If financing is secured, these data could improve partnering prospects and create a path toward clinical validation.
Partnership Milestone PotentialThe Indivior collaboration provides non-dilutive upside beyond Addex’s internal resources. Partner-funded development can reduce execution burden, while milestone and royalty rights could support future cash generation if the selected compound advances.
Low Financial LeverageMinimal debt limits interest and refinancing pressure, preserving flexibility for a development-stage company. Although Addex still requires funding, its low leverage means future financing decisions are not compounded by a heavy existing debt burden.
Bears Say
Insufficient Cash For Clinical ProgressionThe limited cash balance constrains Addex’s ability to advance its own programs and makes development timing dependent on new financing or partners. Delays could weaken asset value, reduce negotiating leverage, and increase dilution risk.
Persistent Losses And Cash BurnAddex does not yet generate cash from operations, while substantial R&D and corporate costs continue to produce losses. This structural funding need can persist until partnerships, milestones, or product revenue become meaningful.
Contracting And Variable Revenue BaseDeclining revenue and reliance on irregular partnership receipts make financial performance difficult to forecast. With no marketed products, revenue growth depends on external transactions and program success rather than a recurring commercial base.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was CHF0.03 and its highest was CHF0.09 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is CHF3.18M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Nov 09, 2026 which is in 65 days.
How were Addex Therapeutics’s earnings last quarter?
Addex Therapeutics released its earnings results on Jun 25, 2026. The company reported -CHF0.01 earnings per share for the quarter.
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Undervalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 218,654,500 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Addex Therapeutics reported an EPS of -CHF0.01 in its last earnings report. Following the earnings report the stock price went down -20%.
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in CH:ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.